Moonlake Immunotherapeutics

Case Overview
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 12/15/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Moonlake Immunotherapeutics |
Court: | Court: Southern District of New York |
Case Number: | Case Number: 1:25cv08500 |
Class Period: | Class Period: 03/10/2024 - 09/29/2025 |
Ticker: | Ticker: MLTX |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The suit alleges that MoonLake Immunotherapeutics misled investors about its sole drug candidate, sonelokimab (SLK), which was promoted as superior to competing monoclonal antibodies. The complaint claims MoonLake and its executives repeatedly touted SLK's Nanobody structure as providing unique clinical advantages, while failing to disclose that it targeted the same molecules as UCB's BIMZELX and offered no proven superiority. On September 28, 2025, MoonLake announced Phase 3 results showing SLK failed to match BIMZELX's efficacy, which analysts called a "disastrous result." Following the news, MoonLake's stock collapsed nearly 90%, causing significant losses for investors.